Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013, Article ID 871476, 2 pages
http://dx.doi.org/10.1155/2013/871476
Case Report

Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript

1Hematology Unit and Bone Marrow Transplantation Center, “R. Binaghi” Hospital, Via Is Guadazzonis 3, 09126 Cagliari, Italy
2Hematology, Department of Medical Sciences, University of Cagliari, 09100 Cagliari, Italy

Received 4 June 2013; Accepted 27 June 2013

Academic Editors: E. Arellano-Rodrigo and K. Konstantopoulos

Copyright © 2013 Marianna Greco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Chronic myeloid leukemia (CML) with the rare fusion gene e19a2, encoding a p230 protein, has been described in patients with typical or rather aggressive clinical course. Although tyrosine kinase inhibitors (TKIs) induce a substantial cytogenetic and molecular response in all phases of CML, a minority of p230 positive patients have been treated with TKIs. We report two cases of CML patients carrying the p230 transcript, who achieved fast and deep complete molecular response (CMR) after frontline treatment with nilotinib. Our results suggest the use of nilotinib as frontline agent for the treatment of this CML variant.